Teva Pharma Industries Ltd ADRTEVA
Mentioned
Impact on stocks 1
Health Care▲ · 1 stocks
Teva Pharma Industries Ltd ADRTheme Impact 2
Off-coverage companies
Related news
▲5impact 4
Eisai's Subcutaneous Leqembi Wins Health Ministry Approval, Enabling At-Home Dosing
Eisai and U.S. pharmaceutical giant Biogen announced on the 16th that the subcutaneous formulation of their Alzheimer's disease treatment lecanemab, sold under the brand name Leqembi, has received manufacturing and marketing approval from the Ministry of Health, Labour and Welfare. The product, named Leqembi Subcutaneous Injection 250mg Pen, can be administered in about 15 seconds per pen, with two pens used per dose. Until now, patients needed intravenous infusions at a hospital once every two weeks, but the subcutaneous formulation allows once-weekly self-administration at home, though doctor visits will still be required for prescriptions and safety checks. Following deliberation and approval by the Central Social Insurance Medical Council, prescriptions are expected to begin between mid-November and mid-December. This is the third country to approve the subcutaneous version, after the United States and China.
▲2impact 4
Eli Lilly Hits $1 Trillion Market Cap as 24/7 Wall St. Sets $1,220 Price Target
Eli Lilly has crossed into trillion-dollar territory, trading at $1,123.98 with a market capitalization of $1.002 trillion, and 24/7 Wall St. rates the stock a buy with a 12-month price target of $1,220.42, implying 8.58% upside at 90% confidence. The company's second-quarter 2026 revenue reached $22.974 billion, up 47.67% year over year, with earnings per share of $8.38 beating consensus by 27.27%, and management raised full-year revenue guidance to $85 billion to $87 billion. Mounjaro alone posted $9.94 billion, up 91% year over year, while the incretin franchise generated roughly $14.87 billion of the quarter's revenue. The bull case targets $1,381.62, a 22.92% gain, driven by retatrutide's planned BLA submission in the first quarter of 2027, the oral GLP-1 Foundayo's expansion to 36,000 prescribers, and the Medicare GLP-1 Bridge Program opening access for 20 million eligible Americans at $50 per month. The bear case takes shares to $1,045.34, a 7% decline, citing realized prices that fell 13% in the second quarter, $2.78 billion in acquired IPR&D charges, and net insider selling. Lilly's forward price-to-earnings ratio of 24 compares with 14 for Novo Nordisk, which grew quarterly revenue just 2.1%, and 16 for Merck, whose quarterly earnings shrank 19.3% year over year.
▼
Medical Costs Reach 49.2 Trillion Yen: Explaining the Increase in High-Cost Medical Care Ceilings and System Reforms
According to the latest data from the Ministry of Health, Labour and Welfare, Japan's total medical costs reached 49.2 trillion yen, an increase of about 1.3 trillion yen from the previous year. The growth rate was 2.6 percent. Although the number of days of medical treatment decreased, the rise in medical costs per day pushed up the total. Medical costs for those aged 75 and over were 20.3 trillion yen, accounting for 41.3 percent of the total, with per-person costs of 989,000 yen, about 3.8 times that of those under 75. From August 2026, the high-cost medical care system will be revised, raising the ceiling on out-of-pocket payments while introducing a new annual cap for long-term patients. Furthermore, under the medical insurance system reform law enacted in fiscal 2026, revisions to benefits for over-the-counter similar drugs, reflection of financial income of late-stage elderly, in-kind provision of childbirth costs, and expansion of insurance premium reductions for households raising children are planned.